Commentary: PROTACs make undruggable targets druggable: Challenge and opportunity.
作者信息
Lu Bin, Ye Jianpin
机构信息
The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China.
Protein Quality Control and Diseases Laboratory, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035, China.
出版信息
Acta Pharm Sin B. 2021 Oct;11(10):3335-3336. doi: 10.1016/j.apsb.2021.07.017. Epub 2021 Jul 22.
Abstract
摘要
相似文献
1
Commentary: PROTACs make undruggable targets druggable: Challenge and opportunity.评论：蛋白降解靶向嵌合体（PROTACs）使不可成药靶点变得可成药：挑战与机遇。
Acta Pharm Sin B. 2021 Oct;11(10):3335-3336. doi: 10.1016/j.apsb.2021.07.017. Epub 2021 Jul 22.
2
Light-Controllable PROTACs for Temporospatial Control of Protein Degradation.用于蛋白质降解时空控制的光控PROTAC
Front Cell Dev Biol. 2021 Jul 19;9:678077. doi: 10.3389/fcell.2021.678077. eCollection 2021.
3
PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.PROTACs：药物发现中蛋白质降解的新兴靶向技术。
Bioessays. 2018 Apr;40(4):e1700247. doi: 10.1002/bies.201700247. Epub 2018 Feb 23.
4
Design and pharmaceutical applications of proteolysis-targeting chimeric molecules.蛋白酶靶向嵌合分子的设计及其药学应用
Biochem Pharmacol. 2020 Dec;182:114211. doi: 10.1016/j.bcp.2020.114211. Epub 2020 Aug 29.
5
Targeted protein degradation by PROTACs.通过 PROTACs 进行靶向蛋白降解。
Pharmacol Ther. 2017 Jun;174:138-144. doi: 10.1016/j.pharmthera.2017.02.027. Epub 2017 Feb 14.
6
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.从具有混杂弹头的选择性降解中吸取 PROTAC 设计的经验教训。
Cell Chem Biol. 2018 Jan 18;25(1):78-87.e5. doi: 10.1016/j.chembiol.2017.09.010. Epub 2017 Nov 9.
7
Monitoring and deciphering protein degradation pathways inside cells.监测和解读细胞内的蛋白质降解途径。
Drug Discov Today Technol. 2019 Apr;31:61-68. doi: 10.1016/j.ddtec.2018.12.001. Epub 2018 Dec 19.
8
Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway.发现一种依赖Keap1的肽类PROTAC，通过泛素化-蛋白酶体降解途径敲低Tau蛋白。
Eur J Med Chem. 2018 Feb 25;146:251-259. doi: 10.1016/j.ejmech.2018.01.063. Epub 2018 Feb 4.
9
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.募集的 E3 连接酶的取向决定了差异化 PROTAC 底物特异性。
Nat Commun. 2019 Jan 10;10(1):131. doi: 10.1038/s41467-018-08027-7.
10
Delineating the role of cooperativity in the design of potent PROTACs for BTK.阐明协同作用在设计强效 BTK PROTAC 中的作用。
Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):E7285-E7292. doi: 10.1073/pnas.1803662115. Epub 2018 Jul 16.
引用本文的文献
1
Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions.癌症治疗中的蛋白质降解靶向嵌合体：作用机制、设计、临床试验及未来方向。
Drug Deliv Transl Res. 2025 Jun;15(6):1801-1827. doi: 10.1007/s13346-024-01754-z. Epub 2024 Nov 29.
2
Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates.通过细胞穿透肽诱导的嵌合体偶联物诱导的 DHHC3 降解来抑制 PD-L1 治疗 ICB 耐药性癌症。
Cell Death Dis. 2024 Sep 30;15(9):701. doi: 10.1038/s41419-024-07073-y.
3
Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions.靶向蛋白降解（TPD）在免疫治疗中的作用：了解蛋白水解靶向嵌合体（PROTAC）驱动的泛素-蛋白酶体相互作用。
Bioconjug Chem. 2024 Aug 21;35(8):1089-1115. doi: 10.1021/acs.bioconjchem.4c00253. Epub 2024 Jul 11.
4
Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies.基于PROTAC、分子胶和疏水标签技术的表观遗传降解剂概述。
Acta Pharm Sin B. 2024 Feb;14(2):533-578. doi: 10.1016/j.apsb.2023.09.003. Epub 2023 Sep 12.
5
Advancing PROTAC Characterization: Structural Insights through Adducts and Multimodal Tandem-MS Strategies.推进 PROTAC 表征：通过加合物和多模式串联质谱策略获得结构见解。
J Am Soc Mass Spectrom. 2024 Feb 7;35(2):285-299. doi: 10.1021/jasms.3c00342. Epub 2024 Jan 10.
6
Targeting autophagy and beyond: Deconvoluting the complexity of Beclin-1 from biological function to cancer therapy.靶向自噬及其他：剖析从生物学功能到癌症治疗的Beclin-1的复杂性
Acta Pharm Sin B. 2023 Dec;13(12):4688-4714. doi: 10.1016/j.apsb.2023.08.008. Epub 2023 Aug 12.
7
Function, mechanism and drug discovery of ubiquitin and ubiquitin-like modification with multiomics profiling for cancer therapy.泛素及类泛素修饰在癌症治疗中的功能、机制与药物发现及多组学分析
Acta Pharm Sin B. 2023 Nov;13(11):4341-4372. doi: 10.1016/j.apsb.2023.07.019. Epub 2023 Jul 22.
8
PROTACs: A novel strategy for cancer drug discovery and development.PROTACs：癌症药物发现与开发的新策略。
MedComm (2020). 2023 May 29;4(3):e290. doi: 10.1002/mco2.290. eCollection 2023 Jun.
9
Recent Advances in Covalent Drug Discovery.共价药物发现的最新进展
Pharmaceuticals (Basel). 2023 Apr 28;16(5):663. doi: 10.3390/ph16050663.
10
Autophagy and beyond: Unraveling the complexity of UNC-51-like kinase 1 (ULK1) from biological functions to therapeutic implications.自噬及其他：解析UNC-51样激酶1（ULK1）从生物学功能到治疗意义的复杂性
Acta Pharm Sin B. 2022 Oct;12(10):3743-3782. doi: 10.1016/j.apsb.2022.06.004. Epub 2022 Jun 11.
本文引用的文献
1
Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation.靶向蛋白降解嵌合体（PROTACs）步入成熟：进入靶向蛋白降解的第三个十年。
RSC Chem Biol. 2021 Mar 19;2(3):725-742. doi: 10.1039/d1cb00011j.
2
Maintenance of organellar protein homeostasis by ER-associated degradation and related mechanisms.内质网相关降解及相关机制维持细胞器蛋白的稳态。
Mol Cell. 2021 Jun 17;81(12):2507-2519. doi: 10.1016/j.molcel.2021.05.004. Epub 2021 Jun 8.
3
Targeted protein degradation: A promise for undruggable proteins.靶向蛋白降解：不可成药蛋白的新希望。
Cell Chem Biol. 2021 Jul 15;28(7):934-951. doi: 10.1016/j.chembiol.2021.04.011. Epub 2021 May 17.
4
Targeted protein degraders crowd into the clinic.靶向蛋白降解剂纷纷涌入临床。
Nat Rev Drug Discov. 2021 Apr;20(4):247-250. doi: 10.1038/d41573-021-00052-4.
5
Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent.临床综述：维托克洛司作为一种促凋亡和抗纤维化药物
Front Pharmacol. 2020 Nov 26;11:564108. doi: 10.3389/fphar.2020.564108. eCollection 2020.
6
PROTACs: An Emerging Therapeutic Modality in Precision Medicine.蛋白水解靶向嵌合体（PROTACs）：精准医学中的一种新兴治疗模式。
Cell Chem Biol. 2020 Aug 20;27(8):998-1014. doi: 10.1016/j.chembiol.2020.07.020. Epub 2020 Aug 13.
7
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.蛋白水解靶向嵌合体作为治疗方法和生物发现工具。
Cell. 2020 Apr 2;181(1):102-114. doi: 10.1016/j.cell.2019.11.031. Epub 2020 Jan 16.
8
A selective BCL-X PROTAC degrader achieves safe and potent antitumor activity.一种选择性 BCL-XL PROTAC 降解剂可实现安全有效的抗肿瘤活性。
Nat Med. 2019 Dec;25(12):1938-1947. doi: 10.1038/s41591-019-0668-z. Epub 2019 Dec 2.
9
Cellular quality control by the ubiquitin-proteasome system and autophagy.细胞的泛素-蛋白酶体系统和自噬的质量控制。
Science. 2019 Nov 15;366(6467):818-822. doi: 10.1126/science.aax3769. Epub 2019 Nov 14.
10
Targeted protein degradation: expanding the toolbox.靶向蛋白降解：拓展工具盒。
Nat Rev Drug Discov. 2019 Dec;18(12):949-963. doi: 10.1038/s41573-019-0047-y. Epub 2019 Oct 30.
Zotero 插件